Antibody validationStandard antibody validationEnhanced antibody validationProtein array (PA) Standard antibody validation - PAWestern blot (WB)Standard antibody validation - WBEnhanced antibody validation - WBImmunohistochemistry - tissuesStandard antibody validation - IHCEnhanced antibody validation - IHC

Tissue methods

Antibody validation

The usefulness of antibodies in different assays is dependent on both sensitivity and specificity of epitope binding, and in order to provide the best estimate of protein expression across tissues and cells, antibody validation is a crucial part of the Human Protein Atlas. All antibodies are validated by a set of defined criteria, as described below. Only antibodies that pass the minimum criteria of standard antibody validation are published on the Human Protein Atlas. In addition to the standard quality assurance, enhanced antibody validation strategies are performed in an application-specific manner. The different criteria for enhanced antibody validation are described below.

Standard antibody validation

All antibodies produced internally within the Human Protein Atlas project (HPA antibodies) must pass steps 1-4 in the list below in order to be used for immunohistochemistry and immunocytochemistry/IF. Steps 5-7 provide the basis for evaluating and scoring the antibody reliability. All antibodies that provide a reasonable pattern of immunoreactivity are added to the Human Protein Atlas portal. Feedback from the research community is appreciated and needed for continuous curation of data.
Quality assurance steps for antibodies generated within the Human Protein Atlas project:

1. The antigen (protein epitope signature tag (PrEST)) for a protein is selected as a stretch of 20-150 amino acids with as low identity as possible to proteins from all other putative protein-coding genes, and not including signal peptides or transmembrane regions. Multitarget PrESTs are PrESTs that have more than 80% identity to proteins from more than one gene, and are expected to generate antibodies with multiple targets.
2. Plasmid inserts are sequenced to assure that the correct PrEST sequence is cloned.
3. Size of the resulting recombinant protein (including the specific PrEST) is analyzed using mass spectrometry to assure that the correct antigen has been produced and purified.
4. To control for cross-reactivity, affinity purified antibodies are tested for sensitivity and specificity on protein arrays consisting of glass slides with spotted PrEST fragments.
5. Antibody specificity is analyzed using Western blot in a standardized setup. Total protein lysates from a limited number of tissues (liver and tonsil), cell lines (RT4 and U-251 MG), and human plasma are used to evaluate the antibody target binding in a Western blot setting. Antibodies with an uncertain standard Western blot are reanalyzed using an over-expression lysate as a positive control.
6. Immunohistochemical staining of normal and cancer tissue is examined and annotated by specially educated personnel, and the staining patterns are compared with available gene/RNA/protein characterization data.
7. High resolution confocal microscopy images of human cell lines stained by indirect immunofluorescence are annotated for subcellular localizations by trained cell biologists, and the subcellular localization patterns are compared with the immunohistochemical staining and available experimental protein characterization data.

For antibodies supplied through commercial or other academic sources (CAB antibodies), immunocytochemistry and immunohistochemistry have been performed and validated in a similar manner as for HPA antibodies. These antibodies have also been tested on Western blot in a standardized setup. For each commercially available antibody, a link to the antibody provider is given on the "Antibody validation" page. For further validation we refer to quality controls provided by the respective company. Detailed descriptions of the strategies used for standard antibody validation in the different assays are available further down on this page.

Enhanced antibody validation

Antibodies used for Western blot, immunocytochemistry and immunohistochemistry in the Human Protein Atlas undergo enhanced antibody validation based on the five "pillars" described by the International Working Group for Antibody Validation (IWGAV), presented in "A proposal for validation of antibodies" (Uhlen M et al. (2016)). The enhanced validation principles are adapted for validation in Western blot, immunocytochemistry and immunohistochemistry applications. Antibodies that fulfil the criteria are labelled "Enhanced". The following Enhanced antibody validation strategies are used for each assay:

• Immunocytochemistry: Genetic validation, Recombinant expression validation, and Independent antibody validation
• Immunohistochemistry: Orthogonal validation and Independent antibody validation
• Western blot: Genetic validation, Recombinant expression validation, Independent antibody validation, Orthogonal validation, Capture MS validation

Detailed descriptions are available under each section describing the different assays.

Protein array (PA)

All purified antibodies are analyzed on antigen microarrays. The specificity profile for each antibody is determined based on the interaction with 384 different antigens including its own target. The antigens present on the arrays are consecutively exchanged in order to correspond to the next set of 384 purified antibodies. Each microarray is divided into 21 replicated subarrays, enabling the analysis of 21 antibodies simultaneously. The antibodies are detected through a fluorescently labeled secondary antibody and a dual color system is used in order to verify the presence of the spotted proteins. A specificity profile plot is generated for each antibody, where the signal from the binding to its own antigen is compared to the eventual off target interactions to all the other antigens. The vast majority (86%) of antibodies are given a pass and the remaining are failed either due to low signal or low specificity.

Standard antibody validation - PA

Supported

• Pass with single peak corresponding to interaction only with its own antigen.

Approved

• Pass with quality comment low specificity (binding to 1-2 PrESTs >15% and <40% of the signal from the target PrEST).

Uncertain

• No or weak signal.
• Low specificity (one antigen with >40% signal or more than two antigens with signal >15% of the signal from the target PrEST).

Western blot (WB)

Western blot analysis of antibody specificity has been done using a routine sample setup composed of IgG/HSA-depleted human plasma and protein lysates from a limited number of human tissues and cell lines. A selection of antibodies with an uncertain routine WB have been revalidated using an over-expression lysate (VERIFY Tagged Antigen(TM), OriGene Technologies, Rockville, MD) as a positive control. Antibody binding was visualized by chemiluminescence detection in a CCD-camera system using a peroxidase (HRP) labeled secondary antibody.

Antibodies included in the Human Protein Atlas have been analyzed without further efforts to optimize the procedure and therefore it cannot be excluded that certain observed binding properties are due to technical rather than biological reasons and that further optimization could result in a different outcome.

Standard antibody validation - WB

Supported

• Bands corresponding to the predicted size in kDa (+/-20%).
• Band of predicted size in kDa (+/-20%) with additional bands present.

Uncertain

• Single band larger than predicted size in kDa (+20%) but partly supported by predicted transmembrane region, signal peptide or by other available data.
• No bands detected.
• Single band differing more than +/-20% from predicted size in kDa and not supported by predicted transmembrane region, signal peptide or by other available data.
• Weak band of predicted size in kDa (+/-20%) but with additional bands of higher intensity also present.
• Only bands not corresponding to the predicted size.
• Target too small/large to be analyzed with the present setup.
• Current setup is not applicable due to low RNA count

For antibodies showing uncertain Western blot data the corresponding image is not shown.

Enhanced antibody validation - WB

Genetic validation - siRNA

This method is based on the knock-down or knock-out in a suitable cell line of the target protein using genetic methods, such as CRISPR or siRNA. The staining of the antibody is evaluated by Western blot through analyses of samples from cell lysates before and after knock-down of the corresponding target gene. The results show no or weaker band in the lysate from the knock-down cell line.

Antibodies that meet one of the following criteria will receive the validation score “Enhanced” by genetic method:

• Signal downregulation > 25 % by both siRNAs.
• Signal downregulation > 25 % by one siRNA.

Recombinant expression validation

This method is based on over-expression of the target protein in a cell line preferably not expressing the target protein. The staining of the antibody is evaluated by Western blot through analyses of samples from cell lysates with and without recombinant expression of the target protein. The results show no or weak band from the unmodified cell line lysate and a strong band in the cell line with recombinant expression.

Independent antibody validation

This method is based on comparing the staining pattern using two independent antibodies with no overlapping epitopes. The staining of the two antibodies is compared by Western blot through analyses of samples from at least two cell lysates preferably expressing the target protein at different levels. The results show similar Western Blot patterns achieved with independent antibodies.

Orthogonal validation

This method is based on manual evaluation by comparing the antibody band intensity against the corresponding protein levels quantified by mass spectrometry (MS). Antibodies are considered enhanced where the staining intensity and protein expression levels show the same pattern. At least two cell or tissue samples must be used and the target protein must express the target at different levels. This method can also be used to compare the protein expression levels determined by the antibody with the corresponding RNA in each corresponding cell line or tissue.

Capture MS validation

This method is based on comparison between the molecular weight of the stained band visualized by the antibody against the protein size obtained by a capture MS method in which multiple gel slices are cut out from the electrophoretic separation and analysed separately by proteomics. The proteins in each gel slice are digested into peptides and the protein presence and its migration in the gel is verified after the subsequent proteomics analysis. The band detected by the antibody should be equivalent to the same of the intended target protein and its peptide(s).

Immunohistochemistry - tissues

Standard antibody validation - IHC

For each antibody, the observed staining, obtained by immunohistochemistry (IHC), is assigned a validation score. The validation score is based on the result of three different validations that are separately evaluated: literature conformity, RNA consistency and similarity between paired antibodies (several antibodies targeting non-overlapping sequences) with regard to spatial expression pattern.

Literature conformity refers to the conformance of antibody staining in 44 normal tissues with available gene/protein characterization data in scientific literature and data from bioinformatic predictions. UniProt is used as the main source of gene/protein characterization data and when relevant, available publications and other sources of information are researched in depth. Extensive or sufficient gene/protein data requires that there is evidence of existence on the protein level with information on both tissue specificity and subcellular localization, and the tissue specificity was determined using human samples. Limited protein/gene characterization data does not require evidence of existence on the protein level and refers to genes for which only bioinformatic predictions and scarce published experimental data is available. RNA consistency is based on a comparison of antibody staining in 44 normal tissues with RNA-seq data combined from HPA, GTEX and FANTOM. Consistency is categorized as High, Medium, Low, Very low or Cannot be evaluated. Similarity between paired antibodies are evaluated based on staining patterns in 44 normal tissues. The different levels of validation score are Supported, Approved or Uncertain.

Supported
If one of the following criteria is fulfilled:

• At least one antibody shows high or medium consistency between RNA levels and staining pattern, but the antibody does not qualify for Orthogonal validation and staining pattern is consistent with valid literature, or there is no valid literature available
• At least one antibody has RNA consistency defined as “Cannot be evaluated” and staining pattern is consistent with valid literature
• Paired antibodies (several antibodies targeting non-overlapping sequences) show similar staining pattern, but the antibodies do not qualify for Independent antibody validation and staining pattern is consistent with valid literature, or there is no valid literature available

Approved
If one of the following criteria is fulfilled:

• At least one antibody shows high or medium consistency between RNA levels and staining pattern and staining pattern is inconsistent with valid literature
• At least one antibody shows low consistency between RNA levels and staining pattern and staining pattern is consistent with valid literature
• At least one antibody has RNA consistency defined as “Cannot be evaluated” and staining pattern is partly consistent with valid literature, or consistent with limited literature
• Paired antibodies show partly similar expression patterns

Uncertain
If one of the following criteria is fulfilled:

• Only multi-targeting antibodies are available. Multi-targeting antibodies are used for genes where it was not possible to generate single-targeting antibodies due to high sequence identity among proteins belonging to different genes. These genes are in many cases closely related and belong to known gene families, and in these cases a multi-targeting antibody was produced that has >80% sequence identity to transcripts of the genes belonging to the family and low sequence identity to the transcripts of all other human genes.
• At least one antibody shows low or very low consistency between RNA and staining pattern, or RNA consistency is defined as “Cannot be evaluated” and staining pattern is inconsistent with valid literature, or there is no valid literature available
• Paired antibodies show dissimilar expression patterns

Enhanced antibody validation - IHC

Orthogonal validation

Orthogonal validation is based on manual evaluation of the correlation between the staining intensity of a single-target antibody and corresponding mRNA levels across up to 46 normal tissues. For single-target antibodies where consistency between staining intensity and mRNA levels is scored as high or medium, two representative images corresponding to tissues with high and low expression of protein and mRNA are selected. If the difference in mRNA levels between the two representative tissues is at least 4-fold, the antibody will receive the validation score "Enhanced".

Independent antibody validation

This method is based on comparing the staining pattern using two single-target independent antibodies with non-overlapping epitopes. The spatial localization of the staining pattern generated by immunohistochemistry using the two antibodies is compared in 44 different normal tissues. For antibodies that show a similar spatial localization, four representative images are chosen for each antibody. Antibodies that meet the criteria of independent antibody validation will receive the validation score "Enhanced".